Inflammatory Neuropathy Cause and Treatment (INCAT) Scale for the assessment of disability level in patients with chronic inflammatory demyelinating polyneuropathy: linguocultural ratification in Russia

Background. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable dysimmune polyneuropathy. An objective response for pathogenic therapy is essential in diagnosis and management of CIDP. For proper assessment of patient’s complaints and evaluation of disease progression, it is recommended to use validated scales and questionnaires. The paper presents the results of the first step of Inflammatory Neuropathy Cause and Treatment (INCAT) validation in patients with CIDP.
Objective: the development of the Russian version of the INCAT scale and its linguocultural ratification.
Materials and methods. 15 patients with definite CIDP (according to EFNS/PNS criteria) were enrolled. Linguocultural ratification was conducted according to the standard protocol.
Results. The Russian version of the INCAT scale was developed.
Conclusion. We conducted the first stage of INCAT scale validation in patients with CIDP.

1. Van den Bergh P.Y., Hadden R.D., Bouche P. et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. Eur J Neurol 2010;17(3):356–63. DOI: 10.1111/j.1468-1331.2009.02930.x.

2. Bunschoten C., Jacobs B.C., Van den Bergh P.Y. et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol 2019;18(8):784–94. DOI: 10.1016/S1474-4422(19)30144-9.

3. Ikeda S., Koike H., Nishi R. et al. Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2019;90(9):988–96. DOI: 10.1136/jnnp-2019-320741.

4. Вуйцик Н.Б., Супонева Н.А., Чечеткин А.О. и др. Ультразвуковая нейровизуализация при хронической воспалительной демиелинизирующей полиневропатии. Анналы клинической и экспериментальной неврологии 2014;8(3):9–13. [Vuitsyk N.B., Suponeva N.A., Chechetkin A.O. et al. Nerve ultrasound in chronic inflammatory demyelinating polyradiculoneuropathy. Annaly klinicheskoy i eksperimentalnoy nevrologii = Annals of Clinical and Experimental Neurology 2014;8(3):9–13. (In Russ.)].

5. Oaklander A.L., Gimigliano F. Are the treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) effective and safe? A Cochrane Overview summary with commentary. Neur Rehab 2019;44(4):609–12. DOI: 10.3233/NRE-189007.

6. Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J Peripher Nerv Syst 2014;19(1):2–13. DOI: 10.1111/jns5.12053.

7. Merkies I.S., Hughes R.A., Donofrio P. et al. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst 2010;15(3):208–15. DOI: 10.1111/j.1529-8027.2010.00274.x.

8. Merkies I.S.J., Schmitz P.I.M. Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients’ own clinical judgement in immune-mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2006; 77(8):970–2. DOI: 10.1136/jnnp.2005.076174.

9. World Health Organization. Towards a common language for functioning, disability and health (ICF) 2001. Available at: http://www.who.int/classifications/icf/en/.

10. Eftimov F., Vermeulen M., van Doorn P.A. et al. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012;78(14):1079–84. DOI: 10.1212/WNL.0b013e31824e8f84.

11. Nobile-Orazio E., Cocito D., Jann S. et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized controlled trial. Lancet Neurol 2012;11(6):493–502. DOI: 10.1016/S1474-4422(12)70093-5.

12. Hughes R., Bensa S., Willison H. et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50(2):195–201. DOI: 10.1002/ana.1088.

13. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине. М.: ЗАО «Олма Медиа Групп», 2007. 320 с. [Novik A.A., Ionova T.I. The manual for the quality-of-life evaluation in medicine. Moscow: ZAO “Olma Media Grupp”, 2007. 320 p. (In Russ.)].

14. Guillemin F., Bombardier C., Beaton D. Recommendations for the cross-cultural adaptation of health status measures. J Clin Epidemiol 1993;46(12):1417–32. DOI: 10.1016/0895-4356(93)90142-n.